The emerging CAR-T cell therapy, CT041, shows potential in treating advanced pancreatic cancer (PC). This phase I/Ib trial pooled analysis evaluated the safety and efficacy of CT041 in 24 patients with advanced PC. The results demonstrated a median overall survival (mOS) of 10.0 months and a median progression-free survival (mPFS) of 3.3 months.
The most common adverse events were grade 3 or higher hematologic toxicities, cytokine release syndrome (CRS), and gastrointestinal disorders. Despite these side effects, the overall response rate was 16.7%, with a disease control rate of 70.8%. Notably, 70.8% of patients experienced at least a 30% reduction in CA19-9 levels.
These findings suggest that CT041 offers a tolerable safety profile and promising anticancer efficacy. Further studies are needed to confirm these benefits and establish long-term outcomes.
Key Points:
CT041 demonstrated a mOS of 10.0 months and mPFS of 3.3 months in advanced PC.
Common side effects: hematologic toxicities, CRS, and GI disorders.
High disease control rate (70.8%) and significant CA19-9 level reduction.
For more details, read the full study: DOI: 10.1245/s10434-024-15449-9.
Get health updates from Dr Harsh Shah on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
Leave a Reply